Clinical trials
Non-small Lung Cancer clinical trials
Below are recruiting non-small lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04063501Recruiting
Study of gut microbes during immunotherapy for lung cancer
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
New York, New YorkAges 18–100 - NCT04077099RecruitingPhase 1/Phase 2
Study drug for lung cancer with MET changes
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
Birmingham, AlabamaAges 18 years+ - NCT04147078RecruitingPhase 1
Personalized immune vaccine after surgery for certain cancers
This Phase 1 study tests a personalized vaccine made for you to help your immune system after you’ve had surgery or ablation for certain cancers. It’s mainly done to check safety and see how well the vaccine can work at preventing cancer from coming back.
Chengdu, SichuanAges 18–100 - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+ - NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Gilbert, ArizonaAges 18 years+ - NCT04165798Recruiting
Pembrolizumab with or without chemotherapy for stage IV lung cancer
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
Gilbert, ArizonaAges 18 years+ - NCT04210492RecruitingPhase 1/Phase 2
Radiation for centrally located lung cancer, tested in 3 treatments
This trial tests a safer, lower-dose radiation approach given in three sessions for centrally located lung tumors. It aims to deliver effective treatment while protecting nearby sensitive structures like the heart, esophagus, and major airways.
Greenwich, ConnecticutAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT04297605RecruitingPhase 1
Pembrolizumab plus chemotherapy for advanced lung cancer
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
Rochester, New YorkAges 18 years+ - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Duarte, CaliforniaAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04322578RecruitingPhase 2
Crizotinib versus standard chemotherapy for MET exon 14 lung cancer
This study compares crizotinib to standard chemotherapy for people with advanced (spread) non-small cell lung cancer that has a specific change called MET exon 14 skipping. The goal is to see which treatment works better and how safely it controls the cancer.
Changsha, HunanAges 18 years+ - NCT04324125Recruiting
Chemo plus immune therapy for HER2-positive advanced lung cancer
This trial studies whether adding an immune medicine (an antibody that helps your immune system recognize cancer, such as PD-1) to chemotherapy helps people with advanced HER2-positive non-small cell lung cancer. It may be aimed at people who have never had cancer treatment before.
Changsha, HunanAges 18 years+ - NCT04324151Recruiting
Pembrolizumab plus chemotherapy for lung cancer that may be removed
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
Changsha, HunanAges 18 years+ - NCT04322617RecruitingPhase 2/Phase 3
Anlotinib plus immunotherapy for lung cancer after first treatment
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
Changsha, HunanAges 18 years+ - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT04324164Recruiting
Testing outcomes with EGFR pills for uncommon lung cancer mutations
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Changsha, HunanAges 18 years+ - NCT04332367RecruitingPhase 2
New chemo plus ramucirumab for lung cancer after maintenance
This Phase 2 trial studies a combination of chemotherapy (carboplatin and a “taxane”) plus ramucirumab for people with advanced lung cancer that came back or progressed after prior maintenance treatment. It may help by attacking cancer growth after earlier therapy no longer worked.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Los Angeles, CaliforniaAges 18 years+ - NCT04499053RecruitingPhase 2
Durvalumab and tremelimumab with chemotherapy for advanced lung cancer in HIV
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04550104RecruitingPhase 1
Durvalumab with radiation for lung cancer patients
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
BelfastAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+
Hear when a new Non-small Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small lung cancer?
- Yes. Clin2 currently lists 1,123 recruiting non-small lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Lung Cancer, Non-Small Cell
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.